# Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/clinical-modality-of-resistance-and-subsequent-management-of-patients-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yuxin Mu,Xuezhi Hao,Ke Yang,Di Ma,Shouzheng Wang,Ziyi Xu,Junling Li,Puyuan Xing |
| Citations | 40 |
| DOI | 10.1007/s11523-019-00644-6 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://link.springer.com/content/pdf/10.1007/s11523-019-00644-6.pdf |
| OpenAlex ID | https://openalex.org/W2945297162 |
| PMID | 31124059 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Xuezhi Hao](https://scholariq.org/researchers/xuezhi-hao/)

## Paper journal

- [Targeted Oncology](https://scholariq.org/journals/targeted-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.